Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
No pressure, no catch
The supply agreement is designed to support the evaluation of Immuneerings lead candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase II trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy
Common Misconceptions Future Research Directions Useful future work includes standardized definition of the exact copper complex, independent analytical replication, improved pharmacokinetic and toxicology characterization, controlled comparisons between GHK and GHK-Cu, reproducible gene-expression studies, and appropriately designed human research
And a not-insignificant minority of patients point to a lack of efficacyeither insufficient weight reduction or lack of significant decrease in blood glucose levels
10.1038/mt.2012.180 Mol
B., Huang, H
